ETR:MDG1 MediGene Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MediGene AG Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add €4.62 +0.07 (+1.54 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range€4.55Now: €4.62▼€4.6850-Day Range€4.36MA: €4.92▼€5.4052-Week Range€2.91Now: €4.62▼€7.19Volume8,975 shsAverage Volume306,207 shsMarket Capitalization$113.48 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartCompetitorsHeadlines Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase. It also develops Veregen for the treatment of genital warts; and RhuDex for the treatment of autoimmune diseases. Medigene AG has strategic partnership with bluebird bio, Inc. for the development of T cell receptors; and research collaboration agreements with RXi Pharmaceuticals Corporation. The company was founded in 1994 and is headquartered in Munich, Germany.Read More Beat the Market (BTM) Rank™ 3.0 Analyst's Opinion Consensus RatingMediGene has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of €11.00, MediGene has a forecasted upside of 138.1% from its current price of €4.62.Amount of Analyst CoverageMediGene has received no research coverage in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesMediGene has received 148 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMediGene has received 149 “underperform” votes. (Add your “underperform” vote.)Community SentimentMediGene has received 50.17% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about MediGene and other stocks. Vote “Outperform” if you believe MDG1 will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MDG1 will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMediGene does not currently pay a dividend.Dividend GrowthMediGene does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MediGene insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of MediGene is -4.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MediGene is -4.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMediGene has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.10 out of 5 stars Industry, Sector and Symbol Stock Exchange ETR Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolETR:MDG1 Previous Symbol CUSIPN/A CIKN/A Webwww.medigene.de Phone+49-89-2000330Debt Debt-to-Equity Ratio7.09 Current Ratio4.45 Quick Ratio4.45Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$8.57 million Price / Sales13.25 Cash Flow€1.62 per share Price / Cash Flow2.84 Book Value€2.82 per share Price / Book1.64Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees106 Outstanding Shares24,562,700Market Cap$113.48 million Next Earnings DateN/A OptionableNot Optionable €4.62 +0.07 (+1.54 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MDG1 News and Ratings via Email Sign-up to receive the latest news and ratings for MDG1 and its competitors with MarketBeat's FREE daily newsletter. MediGene (ETR:MDG1) Frequently Asked Questions How has MediGene's stock price been impacted by Coronavirus? MediGene's stock was trading at €4.16 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MDG1 shares have increased by 11.2% and is now trading at €4.62. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of MediGene? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediGene in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for MediGene. What price target have analysts set for MDG1? 1 equities research analysts have issued 1 year target prices for MediGene's stock. Their forecasts range from €11.00 to €11.00. On average, they anticipate MediGene's stock price to reach €11.00 in the next twelve months. This suggests a possible upside of 138.1% from the stock's current price. View analysts' price targets for MediGene. Who are some of MediGene's key competitors? Some companies that are related to MediGene include IMV (IMV), Pfenex (PFNX), Pfenex (PFNX), Inventiva (IVA), Ibio (IBIO), Silence Therapeutics (SLN), Neptune Wellness Solutions (NEPT), Ergomed (ERGO), IMV (IMV), ProMetic Life Sciences (PLI), Verona Pharma (VRP), Novacyt (NCYT), Rafael (RFL), Synairgen (SNG) and Burcon NutraScience (BU). View all competitors. What other stocks do shareholders of MediGene own? Based on aggregate information from My MarketBeat watchlists, some companies that other MediGene investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Ampio Pharmaceuticals (AMPE), Apellis Pharmaceuticals (APLS), Aquantia (AQ) and Aquinox Pharmaceuticals (AQXP). Who are MediGene's key executives? MediGene's management team includes the following people: Dr. Horst Domdey, Co-Founder & Chairman of the Supervisory Board (Age 68)Dr. Dolores J. Schendel, CEO, Chief Scientific Officer & Member of Exec. Management BoardDr. Ernst-Ludwig Winnacker, Co-Founder & Chairman Scientific Advisory Board (Age 78)Mr. Axel-Sven Malkomes, CFO, Chief Bus. Devel. Officer and Member of Exec. Management BoardDr. Kai Pinkernell, Chief Medical Officer, Chief Devel. Officer & Member of Exec. Management Board What is MediGene's stock symbol? MediGene trades on the ETR under the ticker symbol "MDG1." What is MediGene's stock price today? One share of MDG1 stock can currently be purchased for approximately €4.62. How big of a company is MediGene? MediGene has a market capitalization of $113.48 million and generates $8.57 million in revenue each year. MediGene employs 106 workers across the globe. What is MediGene's official website? The official website for MediGene is www.medigene.de. How can I contact MediGene? MediGene's mailing address is Lochhamer Strasse 11, PLANEGG, 82152, Germany. The company can be reached via phone at +49-89-2000330. This page was last updated on 9/20/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
